Transforming dry eye care through mechanism-based disease control

Meibum Scientific emerged from decades of real-world clinical observation in the treatment of dry eye disease, blepharitis, and meibomian gland dysfunction. Repeated failures with conventional approaches prompted deeper investigation into the role of biofilm-driven inflammation and gland dysfunction. These observations contributed to the identification of Deep Subdermal Blepharitis (DSB) and the development of a biofilm-centric disease model that underpins Meibum Scientific’s platform, including the REVVE™ protocol. This work established the foundation for a mechanism-based, protocol-driven approach designed to achieve durable disease control rather than transient symptom relief.